serafin daniel (15 Ergebnisse)

Paperback. Zustand: Brand New. 188 pages. 9.00x6.00x0.43 inches. In Stock.

Paperback. Zustand: Brand New. 460 pages. 9.25x6.10x0.91 inches. In Stock.

Zustand: New.

Zustand: New.

Taschenbuch. Zustand: Neu. Neuware -This book constitutes the refereed proceedings of the 11th International Conference on Scalable Uncertainty Management, SUM 2017, which was held in Granada, Spain, in October 2017.The 24 full and 6 short papers presented in this volume were carefully reviewed and selected from 35 submissions. The book also contains 3 invited papers.Managing uncertainty and inconsistency has been extensively explored in Artificial Intelligence over a number of years. Now, with the advent of massive amounts of data and knowledge from distributed, heterogeneous, and potentially conflicting sources, there is interest in developing and applying formalisms for uncertainty and inconsistency in systems that need to better manage this data and knowledge. The International Conference on Scalable Uncertainty (SUM) aims to provide a forum for researchers who are working on uncertainty management, in different communities and with different uncertainty models, to meet and exchange ideas.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 460 pp. Englisch.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book constitutes the refereed proceedings of the 11th International Conference on Scalable Uncertainty Management, SUM 2017, which was held in Granada, Spain, in October 2017. The 24 full and 6 short papers presented in this volume were carefully reviewed and selected from 35 submissions. The book also contains 3 invited papers. Managing uncertainty and inconsistency has been extensively explored in Artificial Intelligence over a number of years. Now, with the advent of massive amounts of data and knowledge from distributed, heterogeneous, and potentially conflicting sources, there is interest in developing and applying formalisms for uncertainty and inconsistency in systems that need to better manage this data and knowledge. The International Conference on Scalable Uncertainty (SUM) aims to provide a forum for researchers who are working on uncertainty management, in different communities and with different uncertainty models, to meet and exchange ideas.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: New. pp. 416 192 Illus. (112 Col.).

Buch. Zustand: Neu. Neuware -The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens Written from the industry perspective and based on many years of experience, this book offers: Concepts for creation of drug-disease models, introduced and supplemented with extensive MATLAB programs Guidance for exploration and modification of these programs to enhance the understanding of key principles Usage of differential equations to pharmacokinetic, pharmacodynamic and (patho-) physiologic problems thereby acknowledging their dynamic nature A range of topics from single exponential decay to adaptive dosing, from single subject exploration to clinical trial simulation, and from empirical to mechanistic disease modeling.Students with an undergraduate mathematical background or equivalent education, interest in life sciences and skills in a high-level programming language such as MATLAB, are encouraged to engage in model-based pharmaceutical research and development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 416 pp. Englisch.

Taschenbuch. Zustand: Neu. Neuware -The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens Written from the industry perspective and based on many years of experience, this book offers: Concepts for creation of drug-disease models, introduced and supplemented with extensive MATLAB programs Guidance for exploration and modification of these programs to enhance the understanding of key principles Usage of differential equations to pharmacokinetic, pharmacodynamic and (patho-) physiologic problems thereby acknowledging their dynamic nature A range of topics from single exponential decay to adaptive dosing, from single subject exploration to clinical trial simulation, and from empirical to mechanistic disease modeling.Students with an undergraduate mathematical background or equivalent education, interest in life sciences and skills in a high-level programming language such as MATLAB, are encouraged to engage in model-based pharmaceutical research and development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 416 pp. Englisch.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens Written from the industry perspective and based on many years of experience, this book offers:- Concepts for creation of drug-disease models, introduced and supplemented with extensive MATLAB programs- Guidance for exploration and modification of these programs to enhance the understanding of key principles- Usage of differential equations to pharmacokinetic, pharmacodynamic and (patho-) physiologic problems thereby acknowledging their dynamic nature- A range of topics from single exponential decay to adaptive dosing, from single subject exploration to clinical trial simulation, and from empirical to mechanistic disease modeling.Students with an undergraduate mathematical background or equivalent education, interest in life sciences and skills in a high-level programming language such as MATLAB, are encouraged to engage in model-based pharmaceutical research and development.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens Written from the industry perspective and based on many years of experience, this book offers:- Concepts for creation of drug-disease models, introduced and supplemented with extensive MATLAB programs- Guidance for exploration and modification of these programs to enhance the understanding of key principles- Usage of differential equations to pharmacokinetic, pharmacodynamic and (patho-) physiologic problems thereby acknowledging their dynamic nature- A range of topics from single exponential decay to adaptive dosing, from single subject exploration to clinical trial simulation, and from empirical to mechanistic disease modeling.Students with an undergraduate mathematical background or equivalent education, interest in life sciences and skills in a high-level programming language such as MATLAB, are encouraged to engage in model-based pharmaceutical research and development.

Hardcover. Zustand: Brand New. 1st edition. 399 pages. 9.20x6.10x1.00 inches. In Stock.

Paperback. Zustand: Brand New. reprint edition. 416 pages. 9.25x6.10x0.98 inches. In Stock.

Hardcover. Zustand: Très bon. Lorenzo Álvarez, Serafín (illustrator). Ancien livre de bibliothèque avec équipements. Edition 2001. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Edition 2001. Ammareal gives back up to 15% of this item's net price to charity organizations.